Admedus HPV Vaccine Heads To The Clinic
Brisbane, Australia, 24 November, 2014 ? Admedus Limited (ASX: AHZ) today announced that its Human Papilloma Virus (HPV) therapeutic vaccine has progressed well in preclinical studies and the company will now advance the programme into a Phase Ib study.
The HPV Vaccine, which is designed to target and clear HPV-positive tumour cells, has shown exceptional preclinical activity in a series of preclinical models. The results show that the therapeutic vaccine prevents disease progression, clears the tumour and inhibits tumour formation.
“The latest preclinical data from the HPV studies is extremely exciting and clearly shows the potential of the technology,” said Mr Lee Rodne, CEO of Admedus. “We now look forward to taking this programme into clinical studies.”
In the TC-1 tumour model, treatment with the HPV vaccine achieved 100% survival and 87.5% (7 of 8) had no detectable tumours after 50 days. In addition, the vaccine provided 100% protection against HPV-positive tumour cell formation, as disclosed previously.
In a similar study, Mkrtichyan et al 2013 published paper showed that following treatment with ADXS-HPV vaccine, none survived beyond day 45. With the addition of the anti-PD-1 antibody, an overall survival rate of 20% after 50 days was achieved.
“The HPV vaccine programme has progressed well and shown some very positive data,” said Professor Ian Frazer. The Admedus Group is progressing the HPV therapeutic vaccine into a Phase Ib study in patients infected with HPV. Admedus anticipates the HPV preclinical data to be published at some time in the future.
Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 3 9620 5454
Media:
Haley Price
+61 (0) 423 139 163
hprice@admedus.com
Media Europe & Asia
Consilium Strategic Communications
Emma Thompson / Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700
admedus@consilium-comms.com
About Admedus Limited
Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group lead by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
About Admedus Vaccines
Admedus Vaccines was founded in 2000 by founder-inventor Professor Ian Frazer as a private, unlisted company to develop and commercialise patented technology for improving immune responses to DNA vaccines, licensed by UniQuest Pty Ltd and developed at the University of Queensland. The company has laboratories within the Translational Research Institute at the Princess Alexandra Hospital in Brisbane. The company’s overall objective is to utilise its unique optimisation technology to produce prophylactic and/or therapeutic DNA vaccines for a range of infectious diseases and cancers in humans.
Help employers find you! Check out all the jobs and post your resume.